Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Medical University of Vienna have developed a new method to systematically boost the therapeutic performance of CAR T cells for the treatment of certain blood cancers. The study, published in Nature , describes their tool called CELLFIE (CRISPR Engineered Library for Functional Interrogation and Enhancement), a high-content CRISPR screening and CAR T-cell engineering method that systematically identifies genetic modifications to improve the performance of CAR T cells for treating cancer.

“Our CELLFIE platform tests knockouts of all human genes in parallel and assesses which ones make CAR T cells fitter, more persistent, or less exhausted,” said first author Paul Datlinger, PhD,

See Full Page